Summary The pre-treatment cell kinetcis of 120 cervical tumours were assessed following the in vivo labelling with the thymidine analogue Bromodeoxyuridine (BrdUrd). In 89% both static and temporal kinetic parameters could be measured. Through the analysis of multiple biopsies from each tumour marked intra tumour heterogeneity was demonstrated. The median values for the most highly labelled sample analysed for each tumour were; S-phase duration (Ts) 12 The minced samples were digested enzymatically for 30 min in a 37°C agitating water bath using a 0.1% pepsin in 0.9% saline solution at pH 1.5. The digest was washed in phosphate buffered saline (PBS) and syringed with a 22 gauge needle to facilitate maximal disaggregation, before filtering the sample through a 40 micron mesh.
The rate at which a tumour proliferates is one of a number of factors important in determining the response of the tumour to cytotoxic therapy (Tubiana & Courdi, 1989) . In rapidly proliferating tumours the problem of tumour repopulation between doses of radiotherapy, with resultant treatment failure, has attracted recent attention due to the potential therapeutic advantage of accelerated hyperfractionated radiotherapy (Fowler, 1986) . Initial results from studies involving altered radiotherapy scheduling and measurement of cell kinetic have shown that patients with rapidly proliferating tumours may benefit from accelerated hyperfractionated schedules (Begg et al., 1992) . The measurement of tumour cell kinetics, particularly in tumours treated with radiotherapy, has therefore gained a new significance, with the possibility of tailoring radiotherapy schedules on the tumour proliferation characterstics.
Many methods for the measurement of tumour proliferation have been introduced over the past 30 years, which in itself indicates that no single technique developed to date has been entirely satisfactory. Early methods involved the incorporation of tritiated thymidine into newly synthesised DNA, therefore precluding their use in patients. Other approaches, including S-phase analysis from DNA histograms, assessment of proliferation associated antigens (for example Ki67) and identification of AgNORs, are only able to define static elements of proliferation, with no evaluation of phase duration. Through the incorporation of the thymidine analogue bromodeoxyuridine (BrdUrd) in vivo, with delayed sampling of the tumour, it is now possible to measure the duration of S-phase in addition to the fraction of proliferating cells, obtaining a more complete assessment of proliferation in vivo than previously feasible (Begg et al., 1985) . If Calculation of bromodeoxyuridine labelling index The total labelling index (TLI), representing the fraction of the entire cell population labelled with Brdu, was determined from the BrdUrd frequency histogram, the distinction between positive and negative cells was determined visually (Figure 1 ). A calculated labelling index (CLI%) was estimated from the BrdUrd/DNA cytogram (Figure 2 ), by identifying labelling associated with a specific tumour ploidy population, and by compensating for those cells which have divided since labelling (Begg et al., 1985 
Calculated cell kinetic parameters
The potential doubling time was derived from the equation:
L is a correction factor for the non-linear distribution of cells through the cell cycle (Steel, 1977 
Analysis ofploidy
The mean number of samples analysed per patient was 2.8 (range 1-6), the mean number of nuclei analysed for each sample was 85,000 (range 20,000-100,000). Coefficient of Table I . There is a significant elevation in BrdUrd labelling in tumour samples but no difference in Ts (P = 0.0001 and P = 0.72 respectively).
Intra tumour heterogeneity
The variation in cell kinetic parameters measured between multiple biopsies from the same tumour was assessed for those tumours where three or more biopsies were analysed and in polyploid tumours where the ploidy of the analysed population was the same in all samples. These criteria were 70.8% satisfied in 21 aneuploid and 22 diploid-tumours, a mean of 3.6 biopsies per patient were analysed, (range 3-6). Each individual measurement for the tumour is expressed as a fraction of the mean for this tumour. In the assessment of intra assay variation each result was expressed as a ratio of the mean for the ten aliquots analysed. The variation in Ts and CLI% measurement seen between multiple biopsies of the same tumour can not be explained by intra assay variation and therefore represent intra tumour heterogeneity, (Table II) . The variation in CLI% is greater than variation in Ts measurement. Cell kinetics and tumour ploidy A significant elevation in CLI% is seen in aneuploid tumours (P = 0.002) but there is no difference in TLI or Ts, (Table  IV) . There is however systematic bias in the measurement of CLI% between diploid and aneuploid tumours due to the admixture of normal cells with diploid tumours only. TLI% measurement, although less precise, does not introduce this bias. No difference in TLI between ploidy groups is seen which suggests that for cervical tumours there is no increase in BrdUrd labelling an aneuploid tumours.
Cell kinetics and clinical parameters A progressive elevation in CLI% is seen with advancing stage (Spearman Rank Correlation r = 0.27, P = .005), no variation in Ts was noted (Figures 4 and 5) . A significant decrease in the Tpot. was seen with increasing stage (Spearman Rank Correlation r = 0.27, P = .005). A similar increase in TLI with tumour stage was also seen (r = 0.24, P = 0.008). An increase in CLI% is also observed in tumours of > 5 cm size compared with tumours < 5 cm (P = .04), but again no difference in Ts was noted (Table III) . To determine the effect of patients age on tumour cell kinetics all women with stage 2B, or more advanced tumours, were analysed following division into three age groups, <45, 45-55, and >55.
No difference is seen in any of the kinetic parameters measured between these groups, ( Table III) .
The relationship between the cell kinetics of the primary tumour and the chance of metastatic disease was analysed in the group of patients who were scheduled for a radical hysterectomy and pelvic lymphadenectomy. Four out of fifteen had histologically proven lymph node metastatic deposits, in three of these four, biopsies from primary and metastatic tumour were obtained. There was no significant difference in the primary tumour cell kinetics dependent on the presence of lymph node involvement, (Table III) . Three of four tumours with lymphatic involvement were diploid, and ploidy of primary and secondary tumour was the same in all cases. No consistent difference in kinetic parameters was seen between the primary and secondary tumour.
Discussion
The study of human tumour cell kinetics has been facilitated by the use of halogenated pyrimidines to label proliferating cells. In addition to the advantage of being able to safely label tumours in vivo, measurement of cell cycle phase duration (Ts) and calculation of Tpot, is now feasible. In a recent review of over 600 tumours labelled with BrdUrd, variation in Ts was almost as great as variation in LI, suggesting that it may be an important parameter (Wilson, 1991 (Wilson, 1991; Bennington, 1969 The presence of aneuploid cell populations in a number of tumour types is associated with higher LI and poor prognosis (Tribukait, 1984; Dressler et al., 1988 Kenter et al., 1990 ).
Prolongation of S-phase has been noted in cancer cells (Steel, 1977 (Tribukait, 1984) . If (Peel et al., 1991) . This study was unable to show a difference in kinetic parameters dependent on age. We do intend to compare single pathological review of all tumours with kinetic parameters measured.
For advanced tumours, in addition to receiving conventional radiotherapy, where appropriate, patients are entered into a phase three study of neo-adjuvant chemotherapy. Analysis of radiotherapy and chemotherapy response in relation to pre treatment tumour cell kinetics will therefore be available in the next few years when adequate follow-up data has been collected. We will also be able to assess the relative importance of mean and maximum values obtained from multiple tumour samples and hope to be able to provide clinical guidelines relating to optimal cervical tumour sampling for the measurement of tumour cell kinetics.
